On the basis of these data, we proposed that chemotherapy combined with HDAC inhibitors might represent a valuable therapeutic option to produce robust and durable benefit for ovarian cancer patients featured by PAX8 dependency. Here, PAX8 is linked to ovarian carcinoma.